New DARZALEX ® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news